NCT06846398

A Phase 2 in Adult Subjects With Hereditary Angioedema

A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2 in Adult Subjects with Hereditary Angioedema

Detailed description

A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects with Hereditary Angioedema

Conditions

• Hereditary Angioedema (HAE)

Interventions

Type	Name	Description
DRUG	BW-20805	SC administrations of BW-20805 600 mg on Day1 to Day673
DRUG	BW-20805	SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673
DRUG	BW-20805	SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589

Timeline

• Start date: 2025-02-28
• Primary completion: 2026-06-30
• Completion: 2028-03-30
• First posted: 2025-02-26
• Last updated: 2026-04-17

Locations

18 sites across 6 countries: United States, China, Germany, Italy, Poland, Spain

Regulatory

• FDA-regulated drug study